NO20003372D0 - Erytropoietinderivater - Google Patents

Erytropoietinderivater

Info

Publication number: NO20003372D0
Authority: NO; Norway
Prior art keywords: erythropoietin derivatives; erythropoietin; derivatives
Prior art date: 1999-07-02

Application number

NO20003372A

Other languages

English (en)

Other versions

NO327043B1 (no

NO20003372L (no

Inventor

Pascal Sebastian Bailon

Original Assignee

Hoffmann La Roche

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1999-07-02

Filing date

2000-06-28

Publication date

2000-06-28

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27495518&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20003372(D0) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2000-06-28 Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche

2000-06-28 Publication of NO20003372D0 publication Critical patent/NO20003372D0/no

2001-01-03 Publication of NO20003372L publication Critical patent/NO20003372L/no

2009-04-06 Publication of NO327043B1 publication Critical patent/NO327043B1/no

Links

OXCMYAYHXIHQOA-UHFFFAOYSA-N potassium;[2-butyl-5-chloro-3-[[4-[2-(1,2,4-triaza-3-azanidacyclopenta-1,4-dien-5-yl)phenyl]phenyl]methyl]imidazol-4-yl]methanol Chemical class [K+].CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C2=N[N-]N=N2)C=C1 OXCMYAYHXIHQOA-UHFFFAOYSA-N 0.000 title 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K17/00—Carrier-bound or immobilised peptides; Preparation thereof
- C07K17/02—Peptides being immobilised on, or in, an organic carrier
- C07K17/08—Peptides being immobilised on, or in, an organic carrier the carrier being a synthetic polymer
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
- C07K14/505—Erythropoietin [EPO]

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Organic Chemistry (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Molecular Biology (AREA)
Genetics & Genomics (AREA)
Biophysics (AREA)
Biochemistry (AREA)
Epidemiology (AREA)
Toxicology (AREA)
Zoology (AREA)
Gastroenterology & Hepatology (AREA)
Virology (AREA)
Communicable Diseases (AREA)
Oncology (AREA)
Diabetes (AREA)
Hematology (AREA)
Neurosurgery (AREA)
Psychiatry (AREA)
AIDS & HIV (AREA)
Urology & Nephrology (AREA)
Tropical Medicine & Parasitology (AREA)
Neurology (AREA)
Biomedical Technology (AREA)
Immunology (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Peptides Or Proteins (AREA)
Medicinal Preparation (AREA)

NO20003372A 1999-07-02 2000-06-28 Konjugat, preparat samt anvendelse derav og fremgangsmate for fremstilling. NO327043B1 (no)

Applications Claiming Priority (4)

Application Number	Priority Date	Filing Date
US14225499P	1999-07-02	1999-07-02
US15022599P	1999-08-23	1999-08-23
US15154899P	1999-08-31	1999-08-31
US16615199P	1999-11-17	1999-11-17

Publications (3)

Publication Number	Publication Date
NO20003372D0 true NO20003372D0 (no)	2000-06-28
NO20003372L NO20003372L (no)	2001-01-03
NO327043B1 NO327043B1 (no)	2009-04-06

Family

ID=27495518

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
NO20003372A NO327043B1 (no)	1999-07-02	2000-06-28	Konjugat, preparat samt anvendelse derav og fremgangsmate for fremstilling.
NO2009010C NO2009010I2 (no)	1999-07-02	2009-05-05	Metoksypolyenglykol-epoetin beta beta

Family Applications After (1)

Application Number	Title	Priority Date	Filing Date
NO2009010C NO2009010I2 (no)	1999-07-02	2009-05-05	Metoksypolyenglykol-epoetin beta beta

Country Status (51)

Country	Link
US (2)	US6583272B1 (no)
EP (2)	EP1839676A3 (no)
JP (2)	JP3727009B2 (no)
KR (1)	KR100593143B1 (no)
CN (2)	CN1184233C (no)
AR (2)	AR024625A1 (no)
AT (1)	ATE370748T1 (no)
AU (1)	AU736067B2 (no)
BG (1)	BG65449B1 (no)
BR (2)	BR0002276A (no)
CA (1)	CA2310536C (no)
CO (1)	CO5190661A1 (no)
CY (2)	CY1107719T1 (no)
CZ (1)	CZ299516B6 (no)
DE (3)	DE60036053T2 (no)
DK (1)	DK1064951T3 (no)
DO (1)	DOP2000000030A (no)
EA (1)	EA003777B1 (no)
ES (2)	ES2289985T3 (no)
FR (2)	FR2795734B1 (no)
GB (2)	GB2393960C (no)
GC (1)	GC0000197A (no)
GE (1)	GEP20022804B (no)
GT (1)	GT200000109A (no)
HR (1)	HRP20000436B1 (no)
HU (1)	HU226233B1 (no)
ID (1)	ID26447A (no)
IL (1)	IL137056A0 (no)
IS (1)	IS2492B (no)
IT (1)	IT1318606B1 (no)
LU (1)	LU91363I2 (no)
MA (1)	MA26746A1 (no)
MX (1)	MXPA00006547A (no)
MY (1)	MY128500A (no)
NL (1)	NL300289I9 (no)
NO (2)	NO327043B1 (no)
NZ (1)	NZ505454A (no)
OA (1)	OA11442A (no)
PA (1)	PA8497801A1 (no)
PE (1)	PE20010297A1 (no)
PL (1)	PL202758B1 (no)
PT (1)	PT1064951E (no)
RS (1)	RS49928B (no)
SG (1)	SG92717A1 (no)
SI (1)	SI1064951T1 (no)
SK (1)	SK286301B6 (no)
SV (1)	SV2002000120A (no)
TN (1)	TNSN00147A1 (no)
TR (1)	TR200001956A2 (no)
TW (1)	TWI235667B (no)
UY (1)	UY26228A1 (no)

Families Citing this family (231)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP1489100B1 (en) *	1997-12-08	2016-06-15	Merck Patent GmbH	Heterodimeric fusion proteins useful for targeted immune therapy and general immune stimulation
US20030105294A1 (en) *	1998-02-25	2003-06-05	Stephen Gillies	Enhancing the circulating half life of antibody-based fusion proteins
RU2229305C2 (ru) *	1998-04-15	2004-05-27	Лексиген Фармасьютикэлс Корпорейшн	Усиление иммунных ответов, опосредованных белками, слитыми из антитела и цитокина, посредством совместного введения ингибитора ангиогенеза
US7304150B1 (en)	1998-10-23	2007-12-04	Amgen Inc.	Methods and compositions for the prevention and treatment of anemia
US7345019B1 (en) *	1999-04-13	2008-03-18	The Kenneth S. Warren Institute, Inc.	Modulation of excitable tissue function by peripherally administered erythropoietin
CZ299516B6 (cs) *	1999-07-02	2008-08-20	F. Hoffmann-La Roche Ag	Konjugát erythropoetinového glykoproteinu, zpusobjeho výroby a použití a farmaceutická kompozice sjeho obsahem
SK782002A3 (en)	1999-07-21	2003-08-05	Lexigen Pharm Corp	FC fusion proteins for enhancing the immunogenicity of protein and peptide antigens
US7067110B1 (en)	1999-07-21	2006-06-27	Emd Lexigen Research Center Corp.	Fc fusion proteins for enhancing the immunogenicity of protein and peptide antigens
JP4793971B2 (ja) *	1999-08-09	2011-10-12	メルクパテントゲーエムベーハー	複合サイトカイン−抗体複合体
US20050202538A1 (en) *	1999-11-12	2005-09-15	Merck Patent Gmbh	Fc-erythropoietin fusion protein with improved pharmacokinetics
EP1228214A2 (en)	1999-11-12	2002-08-07	MERCK PATENT GmbH	Erythropoietin forms with improved properties
HUP0204475A2 (en) *	2000-02-11	2003-04-28	Merck Patent Gmbh	Enhancing the circulating half-life of antibody-based fusion proteins
US6586398B1 (en) *	2000-04-07	2003-07-01	Amgen, Inc.	Chemically modified novel erythropoietin stimulating protein compositions and methods
PL219131B1 (pl) †	2000-05-15	2015-03-31	Hoffmann La Roche	Ciekła kompozycja farmaceutyczna, sposób jej wytwarzania oraz jej zastosowanie
DE60129695T2 (de) *	2000-06-29	2008-06-05	Merck Patent Gmbh	Steigerung von durch antikörper-zytokin-fusionsproteine mediierten immunantworten durch eine kombinierte behandlung mit mitteln zur erhöhung der immunzytokinaufnahme
US20040082765A1 (en) *	2000-10-16	2004-04-29	Teruo Nakamura	Peg-modified erythropoietin
DE60144439D1 (de) *	2000-12-20	2011-05-26	Hoffmann La Roche	Konjugate von erythropoietin (epo) mit polyethylenglykol (peg)
CA2431964C (en) *	2000-12-20	2013-09-10	F. Hoffmann-La Roche Ag	Conjugates of erythropoietin (pep) with polyethylene glycol (peg)
US7767643B2 (en)	2000-12-29	2010-08-03	The Kenneth S. Warren Institute, Inc.	Protection, restoration, and enhancement of erythropoietin-responsive cells, tissues and organs
US20030072737A1 (en) *	2000-12-29	2003-04-17	Michael Brines	Tissue protective cytokines for the protection, restoration, and enhancement of responsive cells, tissues and organs
EP1234583A1 (en) *	2001-02-23	2002-08-28	F. Hoffmann-La Roche Ag	PEG-conjugates of HGF-NK4
AU2002248571B2 (en) *	2001-03-07	2007-01-18	Merck Patent Gmbh	Expression technology for proteins containing a hybrid isotype antibody moiety
DE10112825A1 (de)	2001-03-16	2002-10-02	Fresenius Kabi De Gmbh	HESylierung von Wirkstoffen in wässriger Lösung
WO2002079415A2 (en) *	2001-03-30	2002-10-10	Lexigen Pharmaceuticals Corp.	Reducing the immunogenicity of fusion proteins
PT1383785E (pt)	2001-05-03	2011-06-28	Merck Patent Gmbh	Anticorpo recombinante específico de tumores e utilização deste
US6818613B2 (en)	2001-11-07	2004-11-16	Ortho-Mcneil Pharmaceutical, Inc.	Aqueous sustained-release formulations of proteins
KR100467751B1 (ko)	2001-12-03	2005-01-24	씨제이 주식회사	생체내 에리스로포이에틴 활성이 증진된 융합단백질
PT1454138E (pt)	2001-12-04	2012-03-28	Merck Patent Gmbh	Imunocitoquinas com seletividade modulada
CN102552263A (zh) *	2001-12-06	2012-07-11	法布罗根股份有限公司	提高内源性红细胞生成素(epo)的方法
DE10209822A1 (de)	2002-03-06	2003-09-25	Biotechnologie Ges Mittelhesse	Kopplung niedermolekularer Substanzen an ein modifiziertes Polysaccharid
DE10209821A1 (de)	2002-03-06	2003-09-25	Biotechnologie Ges Mittelhesse	Kopplung von Proteinen an ein modifiziertes Polysaccharid
WO2003078959A2 (en)	2002-03-11	2003-09-25	Ortho Mcneil Pharmaceutical, Inc	Methods for shp1 mediated neuroprotection
CA2491567A1 (en) *	2002-07-01	2004-01-08	The Kenneth S. Warren Institute, Inc.	Recombinant tissue protective cytokines and encoding nucleic acids thereof for protection, restoration, and enhancement of responsive cells, tissues, and organs
WO2004012773A1 (en)	2002-07-24	2004-02-12	F. Hoffmann-La Roche Ag	Polyalkylene glycol acid additives
US7459435B2 (en) *	2002-08-29	2008-12-02	Hoffmann-La Roche Inc.	Treatment of disturbances of iron distribution
DE60332358D1 (de) *	2002-09-09	2010-06-10	Hanall Pharmaceutical Co Ltd	Protease-resistente modifizierte interferon alpha polypeptide
US20050176627A1 (en) *	2002-09-09	2005-08-11	Anthony Cerami	Long acting erythropoietins that maintain tissue protective activity of endogenous erythropoietin
BR0314106A (pt)	2002-09-11	2005-07-19	Fresenius Kabi De Gmbh	Polipeptìdeos hasilados, especialmente eritropoietina hasilada
US7459436B2 (en) *	2002-11-22	2008-12-02	Hoffmann-La Roche Inc.	Treatment of disturbances of iron distribution
US7388079B2 (en) *	2002-11-27	2008-06-17	The Regents Of The University Of California	Delivery of pharmaceutical agents via the human insulin receptor
CN100432105C (zh) *	2002-12-17	2008-11-12	默克专利有限公司	与gd2结合的小鼠14.18抗体的人源化抗体(h14.18)以及其与il-2的融合
US7553930B2 (en)	2003-01-06	2009-06-30	Xencor, Inc.	BAFF variants and methods thereof
US20060104968A1 (en)	2003-03-05	2006-05-18	Halozyme, Inc.	Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminogly ycanases
US7610156B2 (en)	2003-03-31	2009-10-27	Xencor, Inc.	Methods for rational pegylation of proteins
EP1610825A2 (en)	2003-03-31	2006-01-04	Xencor, Inc.	Methods for rational pegylation of proteins
US7642340B2 (en)	2003-03-31	2010-01-05	Xencor, Inc.	PEGylated TNF-α variant proteins
US7279174B2 (en) *	2003-05-08	2007-10-09	Advanced Cardiovascular Systems, Inc.	Stent coatings comprising hydrophilic additives
WO2004100997A2 (en)	2003-05-12	2004-11-25	Affymax, Inc.	Spacer moiety for poly(ethylene glycol) -modified peptides
JP2007530440A (ja) *	2003-05-12	2007-11-01	アフィーマックス・インコーポレイテッド	新規ポリ（エチレングリコール）修飾化合物およびその用途
SI1625156T1 (sl) *	2003-05-12	2013-02-28	Affymax, Inc.	Peptidi, ki se veĹľejo k eritropoetinskemu receptorju
JP4266028B2 (ja)	2003-05-12	2009-05-20	アフィーマックス・インコーポレイテッド	エリスロポエチン受容体に結合する新規ペプチド
KR20060032140A (ko) *	2003-05-30	2006-04-14	센토코 인코포레이티드	트랜스글루타미나아제를 이용한 신규 에리트로포이에틴접합체의 형성
WO2005011587A2 (en) *	2003-07-30	2005-02-10	New Century Pharmaceuticls	Chalaropsis lysozyme protein and its method of use in anti-bacterial applications
WO2005014655A2 (en)	2003-08-08	2005-02-17	Fresenius Kabi Deutschland Gmbh	Conjugates of hydroxyalkyl starch and a protein
BRPI0414887A (pt) *	2003-09-29	2006-12-12	Warren Pharmaceuticals Inc E T	métodos de tratamento, prevenção, retardo do inìcio ou redução dos efeitos de citocinas pró-inflamatórias em um mamìfero e de tratamento, prevenção, retardo do inìcio de uma condição associada com um efeito de citocinas pró-inflamatórias em um mamìfero, e, composição farmacêutica
EP1675871A2 (en)	2003-10-10	2006-07-05	Xencor Inc.	Protein based tnf-alpha variants for the treatment of tnf-alpha related disorders
EP1696947B1 (en) *	2003-12-19	2014-02-26	F.Hoffmann-La Roche Ag	Use of erythropoietin in the treatment of disturbances of iron distribution in chronic inflammatory intestinal diseases
EP1548031A1 (en) *	2003-12-22	2005-06-29	Dubai Genetics FZ-LLC	Nature-identical erythropoietin
JP2008504008A (ja) *	2003-12-31	2008-02-14	メルク　パテント　ゲゼルシャフト　ミット　ベシュレンクテル　ハフトング	改良された薬物動態を有するＦｃ−エリスロポエチン融合タンパク質
ES2720078T3 (es) *	2004-01-21	2019-07-17	Nektar Therapeutics	Método para preparar polímeros terminados en ácido propiónico
CN1942589A (zh) *	2004-02-02	2007-04-04	Ambrx公司	经修饰的人类生长激素多肽与其用途
TWI417303B (zh)	2004-03-11	2013-12-01	Fresenius Kabi De Gmbh	經由還原胺化作用製得之羥烷基澱粉及蛋白質的接合物
US7588745B2 (en) *	2004-04-13	2009-09-15	Si Options, Llc	Silicon-containing products
US7253650B2 (en)	2004-05-25	2007-08-07	International Business Machines Corporation	Increase productivity at wafer test using probe retest data analysis
WO2006062685A2 (en) *	2004-11-11	2006-06-15	Affymax, Inc.	Novel peptides that bind to the erythropoietin receptor
EA200700990A1 (ru) *	2004-11-11	2008-04-28	Афимакс, Инк.	Новые пептиды, которые связывают рецептор эритропоэтина
WO2006081249A2 (en)	2005-01-25	2006-08-03	Cell Therapeutics, Inc.	Conjugates of biologically active proteins having a modified in vivo half-life
EP1848461A2 (en) *	2005-02-16	2007-10-31	Nektar Therapeutics Al, Corporation	Conjugates of an epo moiety and a polymer
US7919461B2 (en)	2005-06-03	2011-04-05	Affymax, Inc.	Erythropoietin receptor peptide formulations and uses
US7550433B2 (en) *	2005-06-03	2009-06-23	Affymax, Inc.	Erythropoietin receptor peptide formulations and uses
US8324159B2 (en) *	2005-06-03	2012-12-04	Affymax, Inc.	Erythropoietin receptor peptide formulations and uses
US20070072795A1 (en) *	2005-09-28	2007-03-29	Anton Haselbeck	Treatment of neurodegenerative disorders
WO2007041713A1 (en) *	2005-10-04	2007-04-12	Zymogenetics, Inc.	Production and purification of il-29
US8741260B2 (en) *	2005-10-07	2014-06-03	Armagen Technologies, Inc.	Fusion proteins for delivery of GDNF to the CNS
US8124095B2 (en) *	2005-10-07	2012-02-28	Armagen Technologies, Inc.	Fusion proteins for delivery of erythropoietin to the CNS
US8053569B2 (en) *	2005-10-07	2011-11-08	Armagen Technologies, Inc.	Nucleic acids encoding and methods of producing fusion proteins
AU2006304856A1 (en) *	2005-10-21	2007-04-26	Synageva Biopharma Corp.	Glycolated and glycosylated poultry derived therapeutic proteins
US20080171696A1 (en) *	2005-10-21	2008-07-17	Avigenics, Inc.	Pharmacodynamically enhanced therapeutic proteins
US8841255B2 (en)	2005-12-20	2014-09-23	Duke University	Therapeutic agents comprising fusions of vasoactive intestinal peptide and elastic peptides
US20130172274A1 (en) *	2005-12-20	2013-07-04	Duke University	Methods and compositions for delivering active agents with enhanced pharmacological properties
DK1988910T3 (en)	2006-02-28	2018-01-22	Kodiak Sciences Inc	ACRYLOYLOXYETHYLPHOSPHORYLCHOLINE-CONTAINING POLYMER CONJUGATES AND PREPARATION thereof
JP5553506B2 (ja)	2006-03-22	2014-07-16	中外製薬株式会社	エリスロポエチン溶液製剤
PL2054074T3 (pl) *	2006-08-04	2015-03-31	Prolong Pharmaceuticals Llc	Zmodyfikowana erytropoetyna
WO2008022349A2 (en)	2006-08-18	2008-02-21	Armagen Technologies, Inc.	Agents for blood-brain barrier delivery
CN101678079B (zh)	2006-11-28	2013-12-25	韩诺生物制约株式会社	修饰的促红细胞生成素多肽及其治疗用途
TW201307390A (zh) *	2007-02-02	2013-02-16	Amgen Inc	海帕西啶（ｈｅｐｃｉｄｉｎ）、海帕西啶拮抗劑及使用方法
WO2008137066A1 (en) *	2007-05-02	2008-11-13	The Board Of Regents Of The University Of Oklahoma	Use of compacted nucleic acid nanoparticles in non-viral treatments of ocular diseases
CL2008002053A1 (es) *	2007-07-17	2009-05-22	Hoffmann La Roche	Metodo para la purificacion de una eritropoyetina monopeguilada (epompeg) que consiste en proporcionar una solucion que contiene eritropoyetina mono, poli y no peguilada y hacerla pasar por dos pasos de cromatografia de intercambio cationico y metodo para producir epo mpeg que incluye metodo de purificacion.
CL2008002054A1 (es) *	2007-07-17	2009-05-29	Hoffmann La Roche	Metodo para la regeneracion de una columna de cromatografia de intercambio cationico despues de la elusion de eritropoyetina monopeguilada y metodo para obtener una eritropoyetina monopeguilada, incorporando el metodo de regeneracion de la columna de intercambio cationico.
AU2008282496B2 (en)	2007-07-27	2013-04-04	Armagen Technologies, Inc.	Methods and compositions for increasing alpha-iduronidase activity in the CNS
EP2205280B1 (en) *	2007-09-27	2019-09-04	Amgen Inc.	Pharmaceutical formulations
EP2219602A1 (en)	2007-11-15	2010-08-25	Amgen, Inc	Aqueous formulation of erythropoiesis stimulating protein stablised by antioxidants for parenteral administration
US8110651B2 (en)	2008-01-11	2012-02-07	Serina Therapeutics, Inc.	Multifunctional forms of polyoxazoline copolymers and drug compositions comprising the same
US8101706B2 (en)	2008-01-11	2012-01-24	Serina Therapeutics, Inc.	Multifunctional forms of polyoxazoline copolymers and drug compositions comprising the same
ES2500066T3 (es)	2008-01-25	2014-09-30	Amgen, Inc	Anticuerpos frente a ferroportina y métodos de uso
NZ586947A (en)	2008-02-08	2012-11-30	Ambrx Inc	Modified leptin polypeptides and their uses
TWI395593B (zh)	2008-03-06	2013-05-11	Halozyme Inc	可活化的基質降解酵素之活體內暫時性控制
KR20100135291A (ko)	2008-04-14	2010-12-24	할로자임, 아이엔씨	히알루로난 관련 질환 및 상태 치료용 변형된 히알루로니다제 및 그 용도
CA2722600C (en)	2008-05-01	2014-01-21	Amgen Inc.	Anti-hepcidin antibodies and methods of use
EP3412300A1 (en)	2008-06-27	2018-12-12	Duke University	Therapeutic agents comprising elastin-like peptides
MX2011003272A (es)	2008-09-26	2011-04-28	Ambrx Inc	Polipeptidos de eritropoyetina animal modificados y sus usos.
JP6018753B2 (ja)	2008-11-13	2016-11-02	ザ・ジェネラル・ホスピタル・コーポレイションＴｈｅＧｅｎｅｒａｌＨｏｓｐｉｔａｌＣｏｒｐｏｒａｔｉｏｎ	Ｂｍｐ−６の調節によって鉄の恒常性を制御するための方法および組成物
CN103205407B (zh)	2008-12-09	2016-03-16	哈洛齐梅公司	延长的可溶性ph20多肽及其用途
CA2748889A1 (en)	2009-03-18	2010-09-23	Armagen Technologies, Inc.	Compositions and methods for blood-brain barrier delivery of igg-decoy receptor fusion proteins
MX2012000735A (es)	2009-07-30	2012-01-27	Hoffmann La Roche	Separador de columna de cromatografia movible.
WO2011024025A1 (en) *	2009-08-28	2011-03-03	Avesthagen Limited	An erythropoietin analogue and a method thereof
MX2012003282A (es)	2009-09-17	2012-04-30	Baxter Healthcare Sa	Co-formulacion estable de hialuronidasa e inmunoglobulina, y metodos de su uso.
UA107678C2 (uk) *	2009-09-23	2015-02-10	ратіофарм ГмбХ	Процес очищення рекомбінантного людського еритропоетину (епо), епо, очищений таким чином, та фармацевтична композиція, що містить його
JP2013507131A (ja)	2009-10-09	2013-03-04	アーメイゲン・テクノロジーズ・インコーポレイテッド	Ｃｎｓにおけるイズロン酸２−スルファターゼ活性を増加させるための方法および組成物
MX344382B (es)	2009-10-23	2016-12-14	Amgen Inc *	Adaptador de vial y sistema.
US8765432B2 (en)	2009-12-18	2014-07-01	Oligasis, Llc	Targeted drug phosphorylcholine polymer conjugates
BR112012027361A2 (pt) *	2010-04-27	2021-04-27	Scil Technology Gmbh	formulação mia/cd-rap estável.
WO2011156373A1 (en)	2010-06-07	2011-12-15	Amgen Inc.	Drug delivery device
MX348420B (es)	2010-07-20	2017-06-12	Halozyme Inc	Efectos secundarios adversos asociados con la administracion de agentes anti-hialuronano y metodos para mejorar o prevenir los efectos secundarios.
CN103118708B (zh)	2010-09-14	2015-08-26	霍夫曼-拉罗奇有限公司	用于纯化聚乙二醇化的促红细胞生成素的方法
RU2584176C2 (ru)	2011-02-02	2016-05-20	Ф. Хоффманн-Ля Рош Аг	Держатель для хроматографической колонки
EP2907504B1 (en)	2011-02-08	2017-06-28	Halozyme, Inc.	Composition and lipid formulation of a hyaluronan-degrading enzyme and the use thereof for treatment of benign prostatic hyperplasia
CA2831100C (en)	2011-03-31	2020-02-18	Mark Dominis Holt	Vial adapter and system
EP2699293B8 (en)	2011-04-20	2022-07-20	Amgen Inc.	Autoinjector apparatus
US9993529B2 (en)	2011-06-17	2018-06-12	Halozyme, Inc.	Stable formulations of a hyaluronan-degrading enzyme
ES2675035T3 (es)	2011-10-14	2018-07-05	Amgen, Inc	Inyector y método de ensamblaje
AU2012328880B2 (en)	2011-10-24	2017-02-23	Halozyme, Inc.	Companion diagnostic for anti-hyaluronan agent therapy and methods of use thereof
AU2012346448B2 (en)	2011-12-02	2017-09-14	Armagen, Inc.	Methods and compositions for increasing arylsulfatase A activity in the CNS
EP3130347B1 (en)	2011-12-30	2019-09-18	Halozyme, Inc.	Ph20 polypeptide variants, formulations and uses thereof
HRP20181187T1 (hr)	2012-04-04	2018-09-21	Halozyme, Inc.	Kombinirana terapija s hijaluronidazom i taksanom koji ciljano djeluje na tumor
CN102816227A (zh) *	2012-08-30	2012-12-12	深圳赛保尔生物药业有限公司	回收促红细胞生成素的方法
WO2014062856A1 (en)	2012-10-16	2014-04-24	Halozyme, Inc.	Hypoxia and hyaluronan and markers thereof for diagnosis and monitoring of diseases and conditions and related methods
EP3656426B1 (en)	2012-11-21	2023-05-17	Amgen Inc.	Drug delivery device
US9657098B2 (en)	2013-03-15	2017-05-23	Intrinsic Lifesciences, Llc	Anti-hepcidin antibodies and uses thereof
EP2968760B1 (en)	2013-03-15	2024-01-03	Amgen Inc.	Drug cassette, autoinjector, and autoinjector system
CA2904661C (en)	2013-03-15	2022-03-15	Amgen Inc.	Drug cassette, autoinjector, and autoinjector system
SG11201507417RA (en)	2013-03-15	2015-10-29	Amgen Inc	Body contour adaptable autoinjector device
IL292270B2 (en)	2013-03-22	2024-04-01	Amgen Inc	Injector and method of assembly
TW201534726A (zh)	2013-07-03	2015-09-16	Halozyme Inc	熱穩定ｐｈ２０玻尿酸酶變異體及其用途
JP6463361B2 (ja)	2013-09-08	2019-01-30	コディアックサイエンシーズインコーポレイテッドＫｏｄｉａｋＳｃｉｅｎｃｅｓＩｎｃ．	第ｖｉｉｉ因子両性イオンポリマーコンジュゲート
MX373358B (es)	2013-10-24	2020-07-06	Amgen Inc	Inyector y método de montaje.
ES3062706T3 (en)	2013-10-24	2026-04-13	Amgen Inc	Drug delivery system with temperature-sensitive control
WO2015119906A1 (en)	2014-02-05	2015-08-13	Amgen Inc.	Drug delivery system with electromagnetic field generator
KR102496507B1 (ko)	2014-05-07	2023-02-03	암겐 인코포레이티드	충격 감소 요소들을 가진 자동 주사기
US20170103186A1 (en)	2014-06-03	2017-04-13	Amgen Inc.	Systems and methods for supporting patient use of a drug delivery device
US9840553B2 (en)	2014-06-28	2017-12-12	Kodiak Sciences Inc.	Dual PDGF/VEGF antagonists
HRP20190881T1 (hr)	2014-08-28	2019-07-12	Halozyme, Inc.	Kombinacijska terapija s hijaluronan-razgrađujućim enzimom i inhibitorom imunološke kontrolne točke
AU2015321462B2 (en)	2014-09-22	2020-04-30	Intrinsic Lifesciences Llc	Humanized anti-hepcidin antibodies and uses thereof
ES2753391T3 (es)	2014-10-14	2020-04-08	Halozyme Inc	Composiciones de adenosina desaminasa 2 (ADA2), variantes de la misma y métodos de uso de las mismas
EP3206739B1 (en)	2014-10-14	2021-12-01	Amgen Inc.	Drug injection device with visual and audio indicators
KR20210013299A (ko)	2014-10-17	2021-02-03	코디악 사이언시스 인코포레이티드	부티릴콜린에스테라제 양성이온성 중합체 컨쥬게이트
WO2016100781A1 (en)	2014-12-19	2016-06-23	Amgen Inc.	Drug delivery device with proximity sensor
US11357916B2 (en)	2014-12-19	2022-06-14	Amgen Inc.	Drug delivery device with live button or user interface field
US10538589B2 (en)	2015-01-14	2020-01-21	Armagen Inc.	Methods and compositions for increasing N-acetylglucosaminidase (NAGLU) activity in the CNS using a fusion antibody comprising an anti-human insulin receptor antibody and NAGLU
CA2976935C (en)	2015-02-17	2020-03-10	Amgen Inc.	Drug delivery device with vacuum assisted securement and/or feedback
EP3261690B1 (en)	2015-02-27	2021-12-15	Amgen Inc.	Drug delivery device having a needle guard mechanism with a tunable threshold of resistance to needle guard movement
WO2017039786A1 (en)	2015-09-02	2017-03-09	Amgen Inc.	Syringe assembly adapter for a syringe
US11351308B2 (en)	2015-12-09	2022-06-07	Amgen Inc.	Auto-injector with signaling cap
KR102799807B1 (ko)	2015-12-30	2025-04-24	코디악 사이언시스 인코포레이티드	항체 및 이의 접합체
US11154661B2 (en)	2016-01-06	2021-10-26	Amgen Inc.	Auto-injector with signaling electronics
ES2814287T3 (es)	2016-03-15	2021-03-26	Amgen Inc	Reducir la probabilidad de rotura de cristal en dispositivos de administración de fármaco
CN105820232B (zh) *	2016-04-08	2019-05-17	昂德生物药业有限公司	单修饰聚乙二醇重组人促红素的制备方法及其制品和应用
US11541168B2 (en)	2016-04-29	2023-01-03	Amgen Inc.	Drug delivery device with messaging label
WO2017192287A1 (en)	2016-05-02	2017-11-09	Amgen Inc.	Syringe adapter and guide for filling an on-body injector
AU2017263558B2 (en)	2016-05-13	2022-12-22	Amgen Inc.	Vial sleeve assembly
US11238150B2 (en)	2016-05-16	2022-02-01	Amgen Inc.	Data encryption in medical devices with limited computational capability
US11541176B2 (en)	2016-06-03	2023-01-03	Amgen Inc.	Impact testing apparatuses and methods for drug delivery devices
WO2018004842A1 (en)	2016-07-01	2018-01-04	Amgen Inc.	Drug delivery device having minimized risk of component fracture upon impact events
HRP20202077T1 (hr)	2016-07-15	2021-02-19	F. Hoffmann - La Roche Ag	Postupak za pročišćavanje pegiliranog eritropoetina
WO2018034784A1 (en)	2016-08-17	2018-02-22	Amgen Inc.	Drug delivery device with placement detection
WO2018081234A1 (en)	2016-10-25	2018-05-03	Amgen Inc.	On-body injector
US20190358411A1 (en)	2017-01-17	2019-11-28	Amgen Inc.	Injection devices and related methods of use and assembly
MX2019009755A (es)	2017-02-17	2019-10-07	Amgen Inc	Mecanismo de insercion para dispositivo de suministro de farmacos.
US11752258B2 (en)	2017-02-17	2023-09-12	Amgen Inc.	Drug delivery device with sterile fluid flowpath and related method of assembly
CA3050927A1 (en)	2017-03-06	2018-09-13	Brian Stonecipher	Drug delivery device with activation prevention feature
WO2018164829A1 (en)	2017-03-07	2018-09-13	Amgen Inc.	Needle insertion by overpressure
MX2019010671A (es)	2017-03-09	2019-10-21	Amgen Inc	Mecanismo de insercion para dispositivo de administracion de farmacos.
JP2020511499A (ja)	2017-03-20	2020-04-16	エフ．ホフマン−ラロシュアーゲーＦ．Ｈｏｆｆｍａｎｎ−ＬａＲｏｃｈｅＡｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ	赤血球生成刺激タンパク質のインビトロでの糖鎖改変のための方法
SG11201907676PA (en)	2017-03-28	2019-09-27	Amgen Inc	Plunger rod and syringe assembly system and method
MX2019014615A (es)	2017-06-08	2020-02-07	Amgen Inc	Dispositivo de administracion de farmacos accionado por par de torsion.
EP3634539A1 (en)	2017-06-08	2020-04-15	Amgen Inc.	Syringe assembly for a drug delivery device and method of assembly
SG10202110492YA (en)	2017-06-22	2021-11-29	Catalyst Biosciences Inc	Modified membrane type serine protease 1 (mtsp-1) polypeptides and methods of use
MX2019015472A (es)	2017-06-22	2020-02-19	Amgen Inc	Reduccion del impacto/choque de la activacion del mecanismo.
AU2018290302B2 (en)	2017-06-23	2024-02-29	Amgen Inc.	Electronic drug delivery device comprising a cap activated by a switch assembly
EP3651832B1 (en)	2017-07-14	2023-12-13	Amgen Inc.	Needle insertion-retraction system having dual torsion spring system
US11672733B2 (en)	2017-07-21	2023-06-13	Amgen Inc.	Gas permeable sealing member for drug container and methods of assembly
US11617837B2 (en)	2017-07-25	2023-04-04	Amgen Inc.	Drug delivery device with gear module and related method of assembly
WO2019022950A1 (en)	2017-07-25	2019-01-31	Amgen Inc.	DRUG DELIVERY DEVICE WITH CONTAINER ACCESS SYSTEM AND ASSEMBLY METHOD THEREOF
MA49838A (fr)	2017-08-09	2020-06-17	Amgen Inc	Systèm de administration de médicaments avec pression hydraulique-pneumatique de chambre
US11077246B2 (en)	2017-08-18	2021-08-03	Amgen Inc.	Wearable injector with sterile adhesive patch
US11103636B2 (en)	2017-08-22	2021-08-31	Amgen Inc.	Needle insertion mechanism for drug delivery device
EP3691717B1 (en)	2017-10-04	2023-02-08	Amgen Inc.	Flow adapter for drug delivery device
CN111132711B (zh)	2017-10-06	2022-07-01	安进公司	带有联锁组件的药物递送装置及相关组装方法
IL273323B2 (en)	2017-10-09	2024-10-01	Amgen Inc	Drug delivery device with drive assembly and related assembly method
MA50527A (fr)	2017-11-03	2020-09-09	Amgen Inc	Système et approches pour stériliser un dispositif d'administration de médicament
JP2021501616A (ja)	2017-11-06	2021-01-21	アムジエン・インコーポレーテツド	配置及び流量検出を備える薬物送達デバイス
IL273664B1 (en)	2017-11-06	2026-02-01	Amgen Inc	Full-fledged assemblies and related methods
CA3079665A1 (en)	2017-11-10	2019-05-16	Amgen Inc.	Plungers for drug delivery devices
MX2020004996A (es)	2017-11-16	2020-08-27	Amgen Inc	Un mecanismo de pestillo de puerta para un dispositivo de administracion de farmacos.
EP3710089A1 (en)	2017-11-16	2020-09-23	Amgen Inc.	Autoinjector with stall and end point detection
WO2019129878A1 (en)	2017-12-29	2019-07-04	F. Hoffmann-La Roche Ag	Process for providing pegylated protein composition
CN111741770A (zh)	2017-12-29	2020-10-02	豪夫迈·罗氏有限公司	用于提供聚乙二醇化蛋白质组合物的方法
HRP20220041T1 (hr)	2017-12-29	2022-04-15	F. Hoffmann - La Roche Ag	Postupak za dobivanje pegiliranog proteinskog pripravka
MX2020009152A (es)	2018-03-02	2020-11-09	Kodiak Sciences Inc	Anticuerpos de il-6 y constructos de fusion y conjugados de los mismos.
US20190351031A1 (en)	2018-05-16	2019-11-21	Halozyme, Inc.	Methods of selecting subjects for combination cancer therapy with a polymer-conjugated soluble ph20
US10835685B2 (en)	2018-05-30	2020-11-17	Amgen Inc.	Thermal spring release mechanism for a drug delivery device
US11083840B2 (en)	2018-06-01	2021-08-10	Amgen Inc.	Modular fluid path assemblies for drug delivery devices
EP3826699A1 (en)	2018-07-24	2021-06-02	Amgen Inc.	Delivery devices for administering drugs
US12303677B2 (en)	2018-07-24	2025-05-20	Amgen Inc.	Hybrid drug delivery devices with optional grip portion and related method of preparation
MA53379A (fr)	2018-07-24	2021-06-02	Amgen Inc	Dispositifs d'administration pour l'administration de médicaments
WO2020023336A1 (en)	2018-07-24	2020-01-30	Amgen Inc.	Hybrid drug delivery devices with grip portion
CA3103105A1 (en)	2018-07-31	2020-02-06	Amgen Inc.	Fluid path assembly for a drug delivery device
EP3613486B1 (de) *	2018-08-24	2020-10-07	UGA Biopharma GmbH	Verfahren und anlage zur reinigung von epo und/oder einem epo-derivat
MA53724A (fr)	2018-09-24	2021-12-29	Amgen Inc	Systèmes et procédés de dosage interventionnel
MA53718A (fr)	2018-09-28	2022-01-05	Amgen Inc	Ensemble d'activation d'échappement de fil de muscle pour un dispositif d'administration de médicament
TWI857975B (zh)	2018-10-02	2024-10-11	美商安進公司	具有內部力傳遞的用於藥物遞送之注射系統
TW202529830A (zh)	2018-10-05	2025-08-01	美商安進公司	具有劑量指示器之藥物遞送裝置
MA53912A (fr)	2018-10-15	2022-01-19	Amgen Inc	Dispositif d'administration de médicament comprenant un mécanisme d'amortissement
EA202191038A1 (ru)	2018-10-15	2021-07-06	Эмджен Инк.	Способ платформенной сборки для устройства доставки лекарственного средства
AU2019370159B2 (en)	2018-11-01	2025-05-29	Amgen Inc.	Drug delivery devices with partial drug delivery member retraction
TWI831847B (zh)	2018-11-01	2024-02-11	美商安進公司	部分針頭縮回之藥物遞送裝置及其操作方法
EP3873566B1 (en)	2018-11-01	2024-11-27	Amgen Inc.	Drug delivery devices with partial drug delivery member retraction
CA3176021A1 (en)	2018-12-28	2020-07-02	Catalyst Biosciences, Inc.	Modified urokinase-type plasminogen activator polypeptides and methods of use
US11613744B2 (en)	2018-12-28	2023-03-28	Vertex Pharmaceuticals Incorporated	Modified urokinase-type plasminogen activator polypeptides and methods of use
WO2020219482A1 (en)	2019-04-24	2020-10-29	Amgen Inc.	Syringe sterilization verification assemblies and methods
JP7608439B2 (ja)	2019-08-23	2025-01-06	アムジエン・インコーポレーテツド	構成可能な針シールド係合構成要素を備えた薬物送達デバイス及び関連方法
CA3157509A1 (en)	2019-10-10	2021-04-15	Kodiak Sciences Inc.	Methods of treating an eye disorder
CN116194585A (zh)	2020-09-22	2023-05-30	美国杰科实验室有限公司	一种糖基化修饰的促红细胞生成素及其应用
WO2022159414A1 (en)	2021-01-22	2022-07-28	University Of Rochester	Erythropoietin for gastroinfestinal dysfunction
JPWO2022239704A1 (no)	2021-05-10	2022-11-17
KR20240011135A (ko)	2021-05-21	2024-01-25	암젠 인크	약물 용기를 위한 충전 레시피를 최적화하는 방법
WO2023209074A1 (en)	2022-04-28	2023-11-02	Institut National de la Santé et de la Recherche Médicale	Methods of restoring erythropoiesis in patients suffering from a sf3b1 mutant myelodysplastic syndrome by correcting coasy mis-splicing
WO2024094457A1 (en)	2022-11-02	2024-05-10	F. Hoffmann-La Roche Ag	Method for producing glycoprotein compositions
CN116492448A (zh) *	2023-04-12	2023-07-28	深圳赛保尔生物药业有限公司	负载peg-epo及间充质干细胞的组合物、药物及其制备方法
WO2025227129A2 (en)	2024-04-25	2025-10-30	Starrock Pharma Llc	Delivery vehicles comprising proglucagon derived polypeptides and anabolic polypeptides and uses thereof
WO2026030152A1 (en)	2024-07-29	2026-02-05	Amgen Inc.	System and method for assessing transferability of a fill recipe

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4179337A (en)	1973-07-20	1979-12-18	Davis Frank F	Non-immunogenic polypeptides
KR850004274A (ko) *	1983-12-13	1985-07-11	원본미기재	에리트로포이에틴의 제조방법
EP0154316B1 (en)	1984-03-06	1989-09-13	Takeda Chemical Industries, Ltd.	Chemically modified lymphokine and production thereof
JPS6197229A (ja)	1984-10-18	1986-05-15	Chugai Pharmaceut Co Ltd	安定なエリトロポエチン製剤
US4917888A (en)	1985-06-26	1990-04-17	Cetus Corporation	Solubilization of immunotoxins for pharmaceutical compositions using polymer conjugation
US5641663A (en) *	1985-11-06	1997-06-24	Cangene Corporation	Expression system for the secretion of bioactive human granulocyte macrophage colony stimulating factor (GM-CSF) and other heterologous proteins from steptomyces
US4902502A (en)	1989-01-23	1990-02-20	Cetus Corporation	Preparation of a polymer/interleukin-2 conjugate
US5166322A (en)	1989-04-21	1992-11-24	Genetics Institute	Cysteine added variants of interleukin-3 and chemical modifications thereof
US5674534A (en) *	1992-06-11	1997-10-07	Alkermes, Inc.	Composition for sustained release of non-aggregated erythropoietin
NZ250375A (en)	1992-12-09	1995-07-26	Ortho Pharma Corp	Peg hydrazone and peg oxime linkage forming reagents and protein derivatives
US5359030A (en) *	1993-05-10	1994-10-25	Protein Delivery, Inc.	Conjugation-stabilized polypeptide compositions, therapeutic delivery and diagnostic formulations comprising same, and method of making and using the same
US5681811A (en)	1993-05-10	1997-10-28	Protein Delivery, Inc.	Conjugation-stabilized therapeutic agent compositions, delivery and diagnostic formulations comprising same, and method of making and using the same
CN1057534C (zh) *	1993-08-17	2000-10-18	柯瑞英-艾格公司	促红细胞生成素类似物
US5643575A (en) *	1993-10-27	1997-07-01	Enzon, Inc.	Non-antigenic branched polymer conjugates
US5919455A (en) *	1993-10-27	1999-07-06	Enzon, Inc.	Non-antigenic branched polymer conjugates
US5932462A (en) *	1995-01-10	1999-08-03	Shearwater Polymers, Inc.	Multiarmed, monofunctional, polymer for coupling to molecules and surfaces
DE741187T1 (de) *	1995-05-05	1997-04-30	Hoffmann La Roche	Rekombinante Obesitäts-(OB)-Proteine
US5672662A (en)	1995-07-07	1997-09-30	Shearwater Polymers, Inc.	Poly(ethylene glycol) and related polymers monosubstituted with propionic or butanoic acids and functional derivatives thereof for biotechnical applications
US6025324A (en) *	1996-05-15	2000-02-15	Hoffmann-La Roche Inc.	Pegylated obese (ob) protein compositions
TW517067B (en) *	1996-05-31	2003-01-11	Hoffmann La Roche	Interferon conjugates
ES2208798T3 (es) *	1997-09-01	2004-06-16	Aventis Pharma Deutschland Gmbh	Eritropoyetina humana recombinante con un perfil de glicosilacion ventajoso.
WO2000032772A2 (en)	1998-11-30	2000-06-08	Eli Lilly And Company	Erythropoietic compounds
JO2291B1 (en) *	1999-07-02	2005-09-12	اف . هوفمان لاروش ايه جي	Erythropoietin derivatives
CZ299516B6 (cs) *	1999-07-02	2008-08-20	F. Hoffmann-La Roche Ag	Konjugát erythropoetinového glykoproteinu, zpusobjeho výroby a použití a farmaceutická kompozice sjeho obsahem
WO2001068141A2 (en)	2000-03-17	2001-09-20	Maxygen Aps	Dispersions of polypeptide conjugates
US6586398B1 (en)	2000-04-07	2003-07-01	Amgen, Inc.	Chemically modified novel erythropoietin stimulating protein compositions and methods
PL219131B1 (pl) *	2000-05-15	2015-03-31	Hoffmann La Roche	Ciekła kompozycja farmaceutyczna, sposób jej wytwarzania oraz jej zastosowanie

2000
- 2000-06-23 CZ CZ20002386A patent/CZ299516B6/cs not_active IP Right Cessation
- 2000-06-27 US US09/604,938 patent/US6583272B1/en not_active Expired - Lifetime
- 2000-06-27 SK SK987-2000A patent/SK286301B6/sk not_active IP Right Cessation
- 2000-06-28 PT PT00113115T patent/PT1064951E/pt unknown
- 2000-06-28 NZ NZ505454A patent/NZ505454A/en not_active IP Right Cessation
- 2000-06-28 PE PE2000000654A patent/PE20010297A1/es not_active IP Right Cessation
- 2000-06-28 AU AU42744/00A patent/AU736067B2/en not_active Expired
- 2000-06-28 AT AT00113115T patent/ATE370748T1/de active
- 2000-06-28 DO DO2000000030A patent/DOP2000000030A/es unknown
- 2000-06-28 IL IL13705600A patent/IL137056A0/xx active Protection Beyond IP Right Term
- 2000-06-28 ID IDP20000533D patent/ID26447A/id unknown
- 2000-06-28 CA CA002310536A patent/CA2310536C/en not_active Expired - Lifetime
- 2000-06-28 DK DK00113115T patent/DK1064951T3/da active
- 2000-06-28 SI SI200030963T patent/SI1064951T1/sl unknown
- 2000-06-28 ES ES00113115T patent/ES2289985T3/es not_active Expired - Lifetime
- 2000-06-28 EP EP07010693A patent/EP1839676A3/en not_active Withdrawn
- 2000-06-28 EP EP00113115A patent/EP1064951B1/en not_active Expired - Lifetime
- 2000-06-28 NO NO20003372A patent/NO327043B1/no not_active IP Right Cessation
- 2000-06-28 DE DE60036053T patent/DE60036053T2/de not_active Expired - Lifetime
- 2000-06-28 RS YUP-407/00A patent/RS49928B/sr unknown
- 2000-06-28 HR HR20000436A patent/HRP20000436B1/xx not_active IP Right Cessation
- 2000-06-28 TR TR2000/01956A patent/TR200001956A2/xx unknown
- 2000-06-28 DE DE122007000064C patent/DE122007000064I2/de active Active
- 2000-06-29 CO CO00048963A patent/CO5190661A1/es active IP Right Grant
- 2000-06-29 GE GEAP20005430A patent/GEP20022804B/en unknown
- 2000-06-29 SG SG200003658A patent/SG92717A1/en unknown
- 2000-06-29 PA PA20008497801A patent/PA8497801A1/es unknown
- 2000-06-29 AR ARP000103318A patent/AR024625A1/es active IP Right Grant
- 2000-06-29 CN CNB001078895A patent/CN1184233C/zh not_active Expired - Lifetime
- 2000-06-29 GT GT200000109A patent/GT200000109A/es unknown
- 2000-06-29 MY MYPI20002954A patent/MY128500A/en unknown
- 2000-06-29 CN CNB2004100036029A patent/CN1283664C/zh not_active Expired - Lifetime
- 2000-06-30 MX MXPA00006547A patent/MXPA00006547A/es active IP Right Grant
- 2000-06-30 TN TNTNSN00147A patent/TNSN00147A1/fr unknown
- 2000-06-30 GB GB0400086A patent/GB2393960C/en not_active Expired - Lifetime
- 2000-06-30 IT IT2000MI001479A patent/IT1318606B1/it active
- 2000-06-30 TW TW089112948A patent/TWI235667B/zh not_active IP Right Cessation
- 2000-06-30 SV SV2000000120A patent/SV2002000120A/es active IP Right Grant
- 2000-06-30 IS IS5554A patent/IS2492B/is unknown
- 2000-06-30 HU HU0002553A patent/HU226233B1/hu active Protection Beyond IP Right Term
- 2000-06-30 GB GB0016205A patent/GB2353281B/en not_active Expired - Lifetime
- 2000-06-30 OA OA1200000197A patent/OA11442A/fr unknown
- 2000-06-30 ES ES200001625A patent/ES2191511B1/es not_active Expired - Fee Related
- 2000-06-30 DE DE10031839A patent/DE10031839A1/de not_active Ceased
- 2000-06-30 KR KR1020000036976A patent/KR100593143B1/ko not_active Expired - Lifetime
- 2000-06-30 UY UY26228A patent/UY26228A1/es not_active IP Right Cessation
- 2000-06-30 BG BG104570A patent/BG65449B1/bg unknown
- 2000-06-30 MA MA26014A patent/MA26746A1/fr unknown
- 2000-07-02 GC GCP2000749 patent/GC0000197A/en active
- 2000-07-03 JP JP2000201525A patent/JP3727009B2/ja not_active Expired - Lifetime
- 2000-07-03 EA EA200000607A patent/EA003777B1/ru not_active IP Right Cessation
- 2000-07-03 FR FR0008609A patent/FR2795734B1/fr not_active Expired - Lifetime
- 2000-07-03 BR BR0002276-4A patent/BR0002276A/pt not_active IP Right Cessation
- 2000-07-03 BR BRPI0002276A patent/BRPI0002276B8/pt unknown
- 2000-07-03 PL PL341187A patent/PL202758B1/pl not_active IP Right Cessation
2002
- 2002-11-14 US US10/293,551 patent/US20030120045A1/en not_active Abandoned
2003
- 2003-12-17 JP JP2003419520A patent/JP2004155787A/ja active Pending
2006
- 2006-09-25 AR ARP060104175A patent/AR055650A2/es unknown
2007
- 2007-08-23 CY CY20071101097T patent/CY1107719T1/el unknown
- 2007-09-05 NL NL300289C patent/NL300289I9/nl unknown
- 2007-09-06 CY CY200700021C patent/CY2007021I2/el unknown
- 2007-09-12 LU LU91363C patent/LU91363I2/fr unknown
- 2007-10-19 FR FR07C0051C patent/FR07C0051I2/fr active Active
2009
- 2009-05-05 NO NO2009010C patent/NO2009010I2/no unknown

Also Published As

Publication number	Publication date
CA2310536A1 (en)	2001-01-02
ATE370748T1 (de)	2007-09-15
GB2393960A (en)	2004-04-14
ID26447A (id)	2001-01-04
CZ20002386A3 (cs)	2002-04-17
CZ299516B6 (cs)	2008-08-20
SV2002000120A (es)	2002-01-31
HRP20000436A2 (en)	2001-06-30
IL137056A0 (en)	2001-06-14
ITMI20001479A0 (it)	2000-06-30
MXPA00006547A (es)	2004-10-28
GC0000197A (en)	2006-03-29
CA2310536C (en)	2007-09-11
DE122007000064I2 (de)	2010-03-25
PT1064951E (pt)	2007-09-10
NL300289I1 (nl)	2007-11-01
AR055650A2 (es)	2007-08-29
CN1280137A (zh)	2001-01-17
BG104570A (en)	2001-09-28
MA26746A1 (fr)	2004-12-20
GT200000109A (es)	2001-12-21
HRP20000436B1 (en)	2008-01-31
FR07C0051I1 (no)	2007-12-14
IS2492B (is)	2009-02-15
DE122007000064I1 (de)	2008-01-03
CY1107719T1 (el)	2010-07-28
NO2009010I1 (no)	2009-05-25
GEP20022804B (en)	2002-09-25
CY2007021I1 (el)	2009-11-04
NO327043B1 (no)	2009-04-06
DE10031839A1 (de)	2001-02-01
NO2009010I2 (no)	2014-06-02
EA003777B1 (ru)	2003-08-28
BRPI0002276B8 (pt)	2021-05-25
AU736067B2 (en)	2001-07-26
PL341187A1 (en)	2001-01-15
RS49928B (sr)	2008-09-29
TNSN00147A1 (fr)	2005-11-10
KR100593143B1 (ko)	2006-06-26
EP1839676A2 (en)	2007-10-03
FR2795734B1 (fr)	2005-09-30
HU226233B1 (en)	2008-07-28
BR0002276A (pt)	2001-12-11
EA200000607A1 (ru)	2001-02-26
CN1515590A (zh)	2004-07-28
AU4274400A (en)	2001-01-04
HU0002553D0 (en)	2000-08-28
KR20010049676A (ko)	2001-06-15
NO20003372L (no)	2001-01-03
AR024625A1 (es)	2002-10-16
SK9872000A3 (en)	2002-06-04
UY26228A1 (es)	2000-10-31
GB2393960C (en)	2012-08-29
SG92717A1 (en)	2002-11-19
OA11442A (fr)	2004-04-28
LU91363I2 (fr)	2007-11-12
EP1064951B1 (en)	2007-08-22
NL300289I2 (nl)	2010-02-01
IT1318606B1 (it)	2003-08-27
NL300289I9 (nl)	2019-08-21
JP2004155787A (ja)	2004-06-03
LU91363I9 (no)	2018-12-31
DK1064951T3 (da)	2007-10-08
GB2353281A (en)	2001-02-21
GB2353281B (en)	2004-06-09
EP1839676A3 (en)	2008-09-03
DE60036053T2 (de)	2008-01-03
CN1283664C (zh)	2006-11-08
FR2795734A1 (fr)	2001-01-05
IS5554A (is)	2001-01-02
SI1064951T1 (sl)	2007-12-31
HK1068354A1 (en)	2005-04-29
HUP0002553A3 (en)	2005-11-28
YU40700A (sh)	2003-12-31
EP1064951A3 (en)	2002-03-20
MY128500A (en)	2007-02-28
PL202758B1 (pl)	2009-07-31
US6583272B1 (en)	2003-06-24
ES2191511B1 (es)	2005-01-01
HUP0002553A2 (en)	2001-03-28
SK286301B6 (en)	2008-07-07
JP3727009B2 (ja)	2005-12-14
ES2289985T3 (es)	2008-02-16
PE20010297A1 (es)	2001-03-07
BRPI0002276B1 (pt)	2019-05-14
CN1184233C (zh)	2005-01-12
TR200001956A2 (tr)	2001-01-22
DOP2000000030A (es)	2002-07-15
ES2191511A1 (es)	2003-09-01
DE60036053D1 (de)	2007-10-04
JP2001064300A (ja)	2001-03-13
FR07C0051I2 (fr)	2008-05-09
BG65449B1 (bg)	2008-08-29
US20030120045A1 (en)	2003-06-26
GB0400086D0 (en)	2004-02-04
GB2393960B (en)	2004-08-04
GB0016205D0 (en)	2000-08-23
NZ505454A (en)	2001-12-21
TWI235667B (en)	2005-07-11
EP1064951A2 (en)	2001-01-03
PA8497801A1 (es)	2001-12-14
CO5190661A1 (es)	2002-08-29
ITMI20001479A1 (it)	2001-12-30
CY2007021I2 (el)	2009-11-04
HK1033328A1 (en)	2001-08-24

Legal Events

Date	Code	Title	Description
2014-06-02	SPCG	Granted supplementary protection certificate	Free format text: PRODUCT NAME: METOKSYPOLYENGLYKOL-EPOETIN BETA BETA (MIRCERA); NAT. REGISTRATION NO/DATE: EU107400001-16 20070903; FIRST REGISTRATION: GB EU107400001-16 20070720 Spc suppl protection certif: 2009010 Filing date: 20090505 Extension date: 20220720
2018-08-20	SPCG	Granted supplementary protection certificate	Free format text: PRODUCT NAME: METOKSYPOLYENGLYKOL-EPOETIN BETA BETA; REG. NO/DATE: EU107400001-16 20070903 Spc suppl protection certif: 2009010 Filing date: 20090505 Extension date: 20220724
2020-07-13	MK1K	Patent expired
2022-08-15	SPCX	Expiry of an spc	Spc suppl protection certif: 2009010

Publication	Publication Date	Title
DK1064951T3 (da)	2007-10-08	Erythropoietinderivater
NO20000885L (no)	2000-08-25	4-Fenyl-pyridin-derivater
NO20021077L (no)	2002-03-05	Amino-triazolopyridin-derivater
ATE293104T1 (de)	2005-04-15	Thiazolylamid-derivate
ATE263748T1 (de)	2004-04-15	Admantan-derivate
EE200100613A (et)	2003-02-17	13-metüülerütromütsiini derivaadid
DK1187814T3 (da)	2004-12-20	5-phenyl-pyrimidinderivater
ATE338021T1 (de)	2006-09-15	Substituierte 2-dialkylaminoalkylbiphenyl- derivate
NO20021803D0 (no)	2002-04-17	Isoksazolkarboksamid-derivater
ATE257148T1 (de)	2004-01-15	Propargyletherderivate
DK1154988T3 (da)	2004-11-22	Mevinolinderivater
ATE374747T1 (de)	2007-10-15	Monofluoralkylderivate
ATE293592T1 (de)	2005-05-15	Resorcinderivate
ATE254598T1 (de)	2003-12-15	4-hydroxybiphenylhydrazid-derivate
DK1187815T3 (da)	2006-06-19	4-phenyl-pyrimidinderivater
DK1189886T3 (da)	2006-05-15	Ethansulfonyl-piperidinderivater
NO20020212D0 (no)	2002-01-15	3-amino-2-benzyl-1-fenyl-propanderivater
NO20022867D0 (no)	2002-06-14	Syklopentenon-derivater
DK1178984T3 (da)	2003-06-10	1-trifluormethyl-4-hydroxy-7-piperidinylaminomethylchroman-derivater
ATE269328T1 (de)	2004-07-15	1-cycloalkylpyrazolyl-benzoyl-derivate